Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 20/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21767837 | 0.93 | CASR (0.49) | CASR | |
| SCHEMBL21767813 | 0.91 | CASR (0.57) | CASR | |
| SCHEMBL21767834 | 0.90 | CASR (0.62) | CASR | |
| SCHEMBL21767839 | 0.89 | CASR (0.47) | CASR | |
| SCHEMBL21926008 | 0.88 | CASR (0.55) | CASR | |
| SCHEMBL21767878 | 0.88 | CASR (0.55) | CASR | |
| SCHEMBL21767849 | 0.87 | CASR (0.56) | CASR | |
| SCHEMBL21926013 | 0.86 | CASR (0.52) | CASR | |
| SCHEMBL21767870 | 0.85 | CASR (0.51) | CASR | |
| SCHEMBL21928752 | 0.85 | CASR (0.56) | CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919891-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-16 | — | — | US | disclosed |
| US-10919891-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-16 | — | — | US | disclosed |
| US-10875862-B2 | — | — | 2020-12-29 | — | — | US | disclosed |
| US-10875862-B2 | — | — | 2020-12-29 | — | — | US | disclosed |
| US-20200131174-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
| US-20200131174-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
| EP-3617209-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919891-B2 | Heterocyclic compound | CASR, AGTR2, AGTR1 | CASR 1/4885 |
| US-20200131174-A1 | HETEROCYCLIC COMPOUND | CASR, AGTR2, AGTR1 | CASR 1/4885 |
| US-10875862-B2 | — | CASR, AGTR2, AGTR1 | CASR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.